[Lynch syndrome: What is new?]

Area of Science:

• Genetics
• Oncology
• Molecular Biology

Background:

• Lynch syndrome is an inherited condition caused by germline mutations in DNA mismatch repair (MMR) genes.
• It predisposes individuals to various cancers, notably colorectal cancer (CRC) and endometrial cancer (EC), accounting for 3% and 2% of these cancers, respectively.
• A family history of cancer, often meeting Amsterdam or Bethesda criteria, is typical.

Purpose of the Study:

• To review the multifaceted aspects of Lynch syndrome.
• To highlight recent advancements in the diagnosis and management of Lynch syndrome.
• To emphasize the importance of identifying Lynch syndrome for therapeutic and surveillance strategies.

Main Methods:

• Diagnosis involves tumor testing, including MMR immunohistochemistry and PCR for microsatellite instability (MSI).
• Distinguishing Lynch syndrome-related MSI from sporadic MSI due to epigenetic events is key.
• Genetic advancements aid in identifying Lynch syndrome and other rare genetic syndromes.

Main Results:

• Improved diagnostic tools enhance the identification of Lynch syndrome patients.
• Microsatellite instability (MSI) tumors, characteristic of Lynch syndrome, are increasingly responsive to novel treatments like immunotherapy.
• Accurate diagnosis facilitates tailored surveillance protocols for patients and their relatives.

Conclusions:

• Early and accurate diagnosis of Lynch syndrome is critical for effective cancer prevention and treatment.
• The advent of immunotherapy offers new therapeutic avenues for MSI-positive tumors.
• Ongoing research and improved diagnostic techniques are vital for managing Lynch syndrome and related hereditary cancers.